Oxford, UK, 18 January 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a partnership with Room4 a UK based imaging company to deliver new tests for cancer prognosis.
Room4 develops innovative high quality imaging software for pathology. OCB and Room4 have collaborated to develop new prognostic biomarkers for colorectal cancer to use in OCB’s ColoProg test.
Nicholas La Thangue, CSO of Oxford Cancer Biomarkers, commented: “We have had a collaboration with Room4 for some time which has been extremely productive and we are excited to take this collaboration to the next level with a formal partnership. The technology we have developed is a vast improvement on the current methods used to assess colorectal cancer prognosis and we expect these methods will be applicable to other cancer indications.”
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. For more information, please visit http://www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743.
For more information please visit: http://www.room4.eu